Key result
Pre-existing immunity to Norovirus GII-4 did not impair de novo immune responses to the novel GII-12 antigen in mice, suggesting a lack of original antigenic sin.
Answers are grounded in this paper and cite their sources.
May guide norovirus vaccine antigen selection; leaves open human translation.
Noroviruses (NoVs) are one of the leading causes of acute nonbacterial gastroenteritis in humans of all ages. In the 1990s, NoV genotype GII-4 became responsible for the majority of NoV sporadic gastroenteritis cases and outbreaks worldwide. Vaccine development against NoV GII-4 is underway. At the same time, there is concern of new emerging NoV genotypes, such as GII-12, which has been recently associated with increasing numbers of NoV outbreaks worldwide. The specific question is whether type-specific pre-existing immunity to NoV GII-4 might impair cognate immune response induced by new viral infections or vaccines. Using GII-4 and GII-12 virus-like particles, we tested the impact of the immunity generated against NoV GII-4 on de novo antibody responses to GII-12 in mice. We found that pre-existing immunity to NoV GII-4 did not impair de novo immune response to the novel antigen, therefore suggesting lack of original antigenic sin (OAS).
No takes yet. Share an insight, caveat, or question.
Tamminen et al. (2013) studied Norovirus immunity. Pre-existing immunity to Norovirus GII-4 was evaluated on De novo antibody responses to Norovirus GII-12. Pre-existing immunity to Norovirus GII-4 did not impair de novo immune responses to the novel GII-12 antigen in mice, suggesting a lack of original antigenic sin.
Synapse has enriched 10 related papers. Consider them for comparative context: